hypericin has been researched along with tamoxifen in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Couldwell, WT; Hintona, DR; Lawa, RE; Su, Y; Zhang, W | 1 |
| Couldwell, WT; Hinton, DR; Surnock, AA; Zhang, W | 1 |
| Bremen, D; Grimmel, C; Krajewski, S; Reed, JC; Schabet, M; Trepel, M; Weller, M | 1 |
| Giese, A; Puchner, MJ | 1 |
| Chen, TC; Fry, D; Liebes, L; Su, S | 1 |
| Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W | 1 |
6 other study(ies) available for hypericin and tamoxifen
| Article | Year |
|---|---|
Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C.
Topics: Alkaloids; Anthracenes; Antineoplastic Agents; Apoptosis; Cell Division; DNA Damage; Dose-Response Relationship, Drug; Enzyme Inhibitors; Growth Inhibitors; Humans; In Vitro Techniques; Neuroblastoma; Perylene; Protein Kinase C; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 1995 |
Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report.
Topics: Adult; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brain Neoplasms; Cell Division; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dominance, Cerebral; Dose-Response Relationship, Drug; Female; Frontal Lobe; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Perylene; Radiotherapy, Adjuvant; Reoperation; Tamoxifen; Tumor Cells, Cultured | 1996 |
Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.
Topics: Anthracenes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Protein; Cell Division; Drug Resistance; fas Receptor; Glioma; Humans; Light; Naphthalenes; Perylene; Protein Kinase C; Protein Synthesis Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation.
Topics: Anthracenes; Antineoplastic Agents, Hormonal; Cell Division; Cell Movement; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioma; Humans; Perylene; Protein Kinase C; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2000 |
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Camptothecin; Cell Line; Glioblastoma; Humans; Irinotecan; Naphthalenes; Perylene; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2003 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Down-Regulation; Drug Synergism; Glioblastoma; Growth Inhibitors; Humans; Male; Mice; Mice, Nude; Perylene; Tamoxifen; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2006 |